James R Bell1, Antonia J A Raaijmakers1, Claire L Curl1, Melissa E Reichelt1, Tristan W Harding1, Aier Bei1, Dominic C H Ng2, Jeffrey R Erickson3, Martin Vila Petroff4, Stephen B Harrap1, Lea M D Delbridge5. 1. Department of Physiology, University of Melbourne, Victoria, Australia. 2. Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Victoria, Australia. 3. Department of Physiology, University of Otago, Dunedin, New Zealand. 4. Centro de Investigaciones Cardiovasculares, Conicet La Plata, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata 1900, Argentina. 5. Department of Physiology, University of Melbourne, Victoria, Australia. Electronic address: lmd@unimelb.edu.au.
Abstract
BACKGROUND: Ischemia-related arrhythmic incidence is generally lower in females (vs males), though risk is selectively increased in women with underlying cardiopathology. Ca(2+)/calmodulin dependent kinase II (CaMKII) has been implicated in ischemia/reperfusion arrhythmias, yet the role of CaMKII in the ischemic female heart has not been determined. The aim of this study was to define the role and molecular mechanism of CaMKII activation in reperfusion arrhythmias in male/female hearts. METHODS AND RESULTS: Male and female rat hearts and cardiomyocytes were subjected to multiple arrhythmogenic challenges. An increased capacity to upregulate autophosphorylated CaMKII (P-CaMKII) in Ca(2+)-challenged female hearts was associated with an enhanced ability to maintain diastolic function. In ischemia/reperfusion, female hearts (vs male) exhibited less arrhythmias (59 ± 18 vs 548 ± 9, s, p<0.05), yet had augmented P-CaMKII (2.69 ± 0.30 vs 1.50 ± 0.14, rel. units, p<0.05) and downstream phosphorylation of phospholamban (1.71 ± 0.42 vs 0.90 ± 0.10, p<0.05). In contrast, hypertrophic female hearts had more reperfusion arrhythmias and lower phospholamban phosphorylation. Isolated myocyte experiments (fura-2) confirmed Ca(2+)-handling arrhythmogenic involvement. Molecular analysis showed target specificity of CaMKII was determined by post-translational modification, with CaMKIIδB and CaMKIIδC splice variants selectively co-localized with autophosphorylation and oxidative modifications of CaMKII respectively. CONCLUSIONS: This study provides new mechanistic evidence that CaMKIIδ splice variants are selectively susceptible to autophosphorylation/oxidation, and that augmented generation of P-CaMKIIδB(Thr287) is associated with arrhythmia suppression in the female heart. Collectively these findings indicate that therapeutic approaches based on selective CaMKII splice form targeting may have potential benefit, and that sex-selective CaMKII intervention strategies may be valid.
BACKGROUND:Ischemia-related arrhythmic incidence is generally lower in females (vs males), though risk is selectively increased in women with underlying cardiopathology. Ca(2+)/calmodulin dependent kinase II (CaMKII) has been implicated in ischemia/reperfusion arrhythmias, yet the role of CaMKII in the ischemic female heart has not been determined. The aim of this study was to define the role and molecular mechanism of CaMKII activation in reperfusion arrhythmias in male/female hearts. METHODS AND RESULTS: Male and female rat hearts and cardiomyocytes were subjected to multiple arrhythmogenic challenges. An increased capacity to upregulate autophosphorylated CaMKII (P-CaMKII) in Ca(2+)-challenged female hearts was associated with an enhanced ability to maintain diastolic function. In ischemia/reperfusion, female hearts (vs male) exhibited less arrhythmias (59 ± 18 vs 548 ± 9, s, p<0.05), yet had augmented P-CaMKII (2.69 ± 0.30 vs 1.50 ± 0.14, rel. units, p<0.05) and downstream phosphorylation of phospholamban (1.71 ± 0.42 vs 0.90 ± 0.10, p<0.05). In contrast, hypertrophic female hearts had more reperfusion arrhythmias and lower phospholamban phosphorylation. Isolated myocyte experiments (fura-2) confirmed Ca(2+)-handling arrhythmogenic involvement. Molecular analysis showed target specificity of CaMKII was determined by post-translational modification, with CaMKIIδB and CaMKIIδC splice variants selectively co-localized with autophosphorylation and oxidative modifications of CaMKII respectively. CONCLUSIONS: This study provides new mechanistic evidence that CaMKIIδ splice variants are selectively susceptible to autophosphorylation/oxidation, and that augmented generation of P-CaMKIIδB(Thr287) is associated with arrhythmia suppression in the female heart. Collectively these findings indicate that therapeutic approaches based on selective CaMKII splice form targeting may have potential benefit, and that sex-selective CaMKII intervention strategies may be valid.
Authors: Charles B B Gray; Takeshi Suetomi; Sunny Xiang; Shikha Mishra; Erik A Blackwood; Christopher C Glembotski; Shigeki Miyamoto; B Daan Westenbrink; Joan Heller Brown Journal: J Mol Cell Cardiol Date: 2017-01-07 Impact factor: 5.000
Authors: Alicia Mattiazzi; Rosana A Bassani; Ariel L Escobar; Julieta Palomeque; Carlos A Valverde; Martín Vila Petroff; Donald M Bers Journal: Am J Physiol Heart Circ Physiol Date: 2015-03-06 Impact factor: 4.733
Authors: José Alberto Navarro-García; Angélica Rueda; Tatiana Romero-García; Jennifer Aceves-Ripoll; Elena Rodríguez-Sánchez; Laura González-Lafuente; Carlos Zaragoza; María Fernández-Velasco; Makoto Kuro-O; Luis M Ruilope; Gema Ruiz-Hurtado Journal: Br J Pharmacol Date: 2020-09-15 Impact factor: 8.739
Authors: James R Bell; Claire L Curl; Tristan W Harding; Martin Vila Petroff; Stephen B Harrap; Lea M D Delbridge Journal: Biol Sex Differ Date: 2016-07-07 Impact factor: 5.027
Authors: Lorna J Daniels; Rachel S Wallace; Olivia M Nicholson; Genevieve A Wilson; Fiona J McDonald; Peter P Jones; J Chris Baldi; Regis R Lamberts; Jeffrey R Erickson Journal: Cardiovasc Diabetol Date: 2018-06-14 Impact factor: 9.951